Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.

Siopi M, Mavridou E, Mouton JW, Verweij PE, Zerva L, Meletiadis J.

J Antimicrob Chemother. 2014 Jun;69(6):1611-9. doi: 10.1093/jac/dku023. Epub 2014 Feb 17.

PMID:
24550381
2.

Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints.

Jeans AR, Howard SJ, Al-Nakeeb Z, Goodwin J, Gregson L, Majithiya JB, Lass-Flörl C, Cuenca-Estrella M, Arendrup MC, Warn PA, Hope WW.

J Infect Dis. 2012 Aug 1;206(3):442-52. doi: 10.1093/infdis/jis372. Epub 2012 May 25.

PMID:
22634880
3.

Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model--authors' response.

Siopi M, Mavridou E, Mouton JW, Verweij PE, Zerva L, Meletiadis J.

J Antimicrob Chemother. 2015 Feb;70(2):634-5. doi: 10.1093/jac/dku484. Epub 2014 Dec 8. No abstract available.

PMID:
25488075
4.

Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.

Siopi M, Siafakas N, Vourli S, Zerva L, Meletiadis J.

Antimicrob Agents Chemother. 2015 Jul;59(7):3973-83. doi: 10.1128/AAC.05035-14. Epub 2015 Apr 20.

5.

The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside.

Seyedmousavi S, Mouton JW, Melchers WJ, Brüggemann RJ, Verweij PE.

Drug Resist Updat. 2014 Jul;17(3):37-50. doi: 10.1016/j.drup.2014.06.001. Epub 2014 Jul 5. Review.

PMID:
25066814
6.

Candida and candidaemia. Susceptibility and epidemiology.

Arendrup MC.

Dan Med J. 2013 Nov;60(11):B4698. Review.

PMID:
24192246
7.

Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis.

Mavridou E, Bruggemann RJ, Melchers WJ, Verweij PE, Mouton JW.

Antimicrob Agents Chemother. 2010 Nov;54(11):4758-64. doi: 10.1128/AAC.00606-10. Epub 2010 Aug 23.

8.

Comment on: Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.

Denning DW, Ghnan N, Kwizera R, Osmanov A.

J Antimicrob Chemother. 2015 Feb;70(2):633. doi: 10.1093/jac/dku330. Epub 2014 Aug 23. No abstract available.

PMID:
25151206
9.

In vitro pharmacokinetic/pharmacodynamic modeling of voriconazole activity against Aspergillus species in a new in vitro dynamic model.

Al-Saigh R, Elefanti A, Velegraki A, Zerva L, Meletiadis J.

Antimicrob Agents Chemother. 2012 Oct;56(10):5321-7. doi: 10.1128/AAC.00549-12. Epub 2012 Aug 6.

10.

Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods.

Pfaller MA, Diekema DJ, Ghannoum MA, Rex JH, Alexander BD, Andes D, Brown SD, Chaturvedi V, Espinel-Ingroff A, Fowler CL, Johnson EM, Knapp CC, Motyl MR, Ostrosky-Zeichner L, Sheehan DJ, Walsh TJ; Clinical and Laboratory Standards Institute Antifungal Testing Subcommittee..

J Clin Microbiol. 2009 Oct;47(10):3142-6. doi: 10.1128/JCM.00940-09. Epub 2009 Aug 19.

11.

Epidemiological cutoff values for azoles and Aspergillus fumigatus based on a novel mathematical approach incorporating cyp51A sequence analysis.

Meletiadis J, Mavridou E, Melchers WJ, Mouton JW, Verweij PE.

Antimicrob Agents Chemother. 2012 May;56(5):2524-9. doi: 10.1128/AAC.05959-11. Epub 2012 Feb 13.

12.

Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy.

Huurneman LJ, Neely M, Veringa A, Docobo Pérez F, Ramos-Martin V, Tissing WJ, Alffenaar JW, Hope W.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2336-42. doi: 10.1128/AAC.03023-15. Print 2016 Apr.

13.

In vivo efficacy of voriconazole and posaconazole therapy in a novel invertebrate model of Aspergillus fumigatus infection.

Forastiero A, Bernal-Martínez L, Mellado E, Cendejas E, Gomez-Lopez A.

Int J Antimicrob Agents. 2015 Nov;46(5):511-7. doi: 10.1016/j.ijantimicag.2015.07.007. Epub 2015 Aug 17.

PMID:
26358971
14.

Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis.

Lepak AJ, Marchillo K, Vanhecker J, Andes DR.

Antimicrob Agents Chemother. 2013 Jan;57(1):579-85. doi: 10.1128/AAC.01279-12. Epub 2012 Nov 12.

15.

In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus.

Seyedmousavi S, Meletiadis J, Melchers WJ, Rijs AJ, Mouton JW, Verweij PE.

Antimicrob Agents Chemother. 2013 Feb;57(2):796-803. doi: 10.1128/AAC.00980-12. Epub 2012 Nov 26.

16.

Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles.

van der Linden JW, Camps SM, Kampinga GA, Arends JP, Debets-Ossenkopp YJ, Haas PJ, Rijnders BJ, Kuijper EJ, van Tiel FH, Varga J, Karawajczyk A, Zoll J, Melchers WJ, Verweij PE.

Clin Infect Dis. 2013 Aug;57(4):513-20. doi: 10.1093/cid/cit320. Epub 2013 May 10.

PMID:
23667263
17.

Susceptibility breakpoints for amphotericin B and Aspergillus species in an in vitro pharmacokinetic-pharmacodynamic model simulating free-drug concentrations in human serum.

Elefanti A, Mouton JW, Verweij PE, Zerva L, Meletiadis J.

Antimicrob Agents Chemother. 2014;58(4):2356-62. doi: 10.1128/AAC.02661-13. Epub 2014 Feb 10.

18.

Azole-resistance in Aspergillus: proposed nomenclature and breakpoints.

Verweij PE, Howard SJ, Melchers WJ, Denning DW.

Drug Resist Updat. 2009 Dec;12(6):141-7. doi: 10.1016/j.drup.2009.09.002. Epub 2009 Oct 29. Review.

PMID:
19879181
19.

Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.

Mavridou E, Brüggemann RJ, Melchers WJ, Mouton JW, Verweij PE.

Antimicrob Agents Chemother. 2010 Feb;54(2):860-5. doi: 10.1128/AAC.00931-09. Epub 2009 Nov 16.

20.

Spectrophotometric reading of EUCAST antifungal susceptibility testing of Aspergillus fumigatus.

Meletiadis J, Leth Mortensen K, Verweij PE, Mouton JW, Arendrup MC.

Clin Microbiol Infect. 2017 Feb;23(2):98-103. doi: 10.1016/j.cmi.2016.10.017. Epub 2016 Oct 25.

PMID:
27793736

Supplemental Content

Support Center